IDEXX Bets on AI Scribe to Boost Pet Diagnostic Sales

On September 16, IDEXX Laboratories (NASDAQ:IDXX) quietly announced the purchase of CoVetAI, a fast‑growing veterinary‑software startup whose flagship product sits in the back‑room of a clinic, listening to the conversation between vet and pet owner and turning it into a tidy, searchable record. Think of it as a digital stenographer that also nudges the clinician toward the next logical test.

What makes the move more than just a cute tech add‑on is IDEXX’s massive existing footprint. Over 10,000 clinics worldwide already run on its cloud‑based practice management platform, and CoVetAI will slot straight into that ecosystem, linking up with VetConnect PLUS. In other words, IDEXX gets an instant audience for the new tool. At the same time, CoVetAI is built to play nicely with rival practice‑management systems, meaning the scribe could wander into clinics that don’t currently buy IDEXX hardware or software – a double‑edged sword that widens reach but also dilutes the pull toward IDEXX’s broader suite.

Look at the numbers from IDEXX’s most recent quarter. Revenue jumped 10 % YoY, while its recurring diagnostics segment surged 11 %, driven largely by higher test volumes. The company also installed more than 1,600 inVue Dx analyzers, pushing the total installed base beyond 9,000 units. Those instruments, marketed as AI‑enabled, already hint at a strategy that blends hardware and software to nudge vets toward ordering more tests. An AI scribe could be the missing link, feeding the right patient details to the clinician at the exact moment a decision is made.

But here’s the rub: the price tag for CoVetAI was never disclosed, so we have no clue whether IDEXX overpaid or got a bargain. The press release talks in hopeful terms – “can raise diagnostic use over time” – which sounds nice on paper but is still just a hypothesis. Moreover, because CoVetAI works with competing platforms, a clinic might adopt the scribe without ever dipping deeper into IDEXX’s product garden, limiting any upside for the parent company.

Financially, the picture is mixed. EPS rose 18 % in Q2, but that boost was helped by tax benefits from stock‑based compensation and a favorable currency swing, with organic growth sitting at 15 %. IDEXX also flagged higher spending on commercial and innovation initiatives, so the brighter earnings outlook comes with a heavier cost base. Hedge‑fund ownership crept up by just one fund to 63, suggesting steady but not frantic confidence. Short interest is a modest 3.04 % of float, and the forward P/E sits near 31, indicating the market already expects solid earnings growth and leaves little margin for error.

In the end, the deal is a classic “promise versus proof” scenario. If clinics that adopt CoVetAI start ordering noticeably more diagnostics, the acquisition could be hailed as a masterstroke that accelerates an already volume‑driven business. If the scribe stays a nice‑to‑have add‑on with no measurable lift, it becomes another line‑item eating into a stock that already trades at a premium. The metric to watch will be test volumes at practices that integrate CoVetAI – the numbers will tell whether the AI scribes are just hype or a real revenue driver.